BeyondSpring Inc. announced that the first patient has been enrolled in BeyondSpring's Phase 2 investigator-initiated trial with lead asset, Plinabulin, in combination with Merck's anti-PD-1 therapy Keytruda® (pembrolizumab) and Docetaxel for previously treated patients with metastatic non-small cell lung cancer and progressive disease after immunotherapy (anti-PD-1 /PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Most patients experience disease progression after immune checkpoint inhibitor-based (ICI) treatment regimens. BeyondSpring's triple-combination therapy has the potential to improve ICI resistance and provide a new treatment option for metastatic NSCLC patients previously treated with an immunotherapy.

The study1 is actively recruiting at Peking Union Medical College Hospital in Beijing, China, with Dr. Mengzhao Wang, Chief of the Department of Respiratory and Critical Care Medicine, as principal investigator. Patients will receive the following doses during each three-week cycle (via IV infusions)2: Plinabulin at 30 mg /m2 on Days 1 and 8 Keytruda at 200 mg on Day 1 Docetaxel at 75 mg /m² on Day 1.